Go Pro
→ China is not hedging. It's escaping. (From Behind the Markets) (Ad)tc pixel Free BVXP Stock Alerts

Bioventix (BVXP) Competitors

Bioventix logo
GBX 1,700 -50.00 (-2.86%)
As of 11:26 AM Eastern
Compare

BVXP vs. APH, AGY, BXP, ANCR, and VLG

Should you buy Bioventix stock or one of its competitors? Bioventix's main competitors and comparable companies include Alliance Pharma (APH), Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), and Venture Life Group (VLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bioventix compare to Alliance Pharma?

Bioventix (LON:BVXP) and Alliance Pharma (LON:APH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Bioventix has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 8.8%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend.

20.6% of Bioventix shares are held by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 12.0% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Alliance Pharma's net margin of -6.00%. Bioventix's return on equity of 65.83% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Alliance Pharma -6.00%-5.04%5.98%

Bioventix has higher earnings, but lower revenue than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Alliance Pharma Neutral

Summary

Bioventix beats Alliance Pharma on 8 of the 13 factors compared between the two stocks.

How does Bioventix compare to Allergy Therapeutics?

Bioventix (LON:BVXP) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Bioventix has a net margin of 59.30% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Bioventix's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Allergy Therapeutics Neutral

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bioventix has higher earnings, but lower revenue than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Allergy Therapeutics£57.29M6.19-£52.59M-£0.97N/A

Bioventix has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market.

Summary

Bioventix beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Bioventix compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Beximco Pharmaceuticals' net margin of 16.76%. Bioventix's return on equity of 65.83% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Bioventix 59.30%65.83%54.07%

Beximco Pharmaceuticals has higher revenue and earnings than Bioventix. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Bioventix£12.54M7.08£8.12M£140.5212.10

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.30 beat Bioventix's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Bioventix Neutral

Beximco Pharmaceuticals has a beta of 0.248, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

Bioventix beats Beximco Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Bioventix compare to Animalcare Group?

Bioventix (LON:BVXP) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Bioventix has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 8.8%. Animalcare Group pays an annual dividend of GBX 5.20 per share and has a dividend yield of 1.6%. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Animalcare Group pays out 71.2% of its earnings in the form of a dividend.

Animalcare Group has higher revenue and earnings than Bioventix. Bioventix is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Animalcare Group£89.11M2.60£36.55M£7.3045.89

Bioventix has a net margin of 59.30% compared to Animalcare Group's net margin of 5.70%. Bioventix's return on equity of 65.83% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Animalcare Group 5.70%4.46%2.97%

20.6% of Bioventix shares are held by institutional investors. Comparatively, 14.3% of Animalcare Group shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 30.1% of Animalcare Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Animalcare Group Neutral

Summary

Bioventix beats Animalcare Group on 7 of the 13 factors compared between the two stocks.

How does Bioventix compare to Venture Life Group?

Bioventix (LON:BVXP) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Bioventix has a net margin of 59.30% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 65.83% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Venture Life Group 17.42%7.82%1.56%

Bioventix has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, indicating that its stock price is 78% less volatile than the broader market.

In the previous week, Venture Life Group had 1 more articles in the media than Bioventix. MarketBeat recorded 1 mentions for Venture Life Group and 0 mentions for Bioventix. Bioventix's average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Venture Life Group Neutral

Bioventix has higher earnings, but lower revenue than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Venture Life Group£35.17M2.27£747.21K£4.3715.10

20.6% of Bioventix shares are held by institutional investors. Comparatively, 21.9% of Venture Life Group shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 7.5% of Venture Life Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Bioventix beats Venture Life Group on 7 of the 12 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVXP vs. The Competition

Export
MetricBioventixPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£88.83M£12.66B£7.40B£2.92B
Dividend Yield8.57%2.61%2.53%6.17%
P/E Ratio12.10782.99272.19367.32
Price / Sales7.08758.69631.4983,741.35
Price / Cash30.8996.4679.8927.89
Price / Book7.3912.0013.147.02
Net Income£8.12M£2.83B£3.47B£5.89B
7 Day Performance3.66%2.04%1.38%0.89%
1 Month Performance11.48%6.08%8.62%3.27%
1 Year Performance-32.81%7.74%25.90%22.28%

Bioventix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVXP
Bioventix
N/AGBX 1,700
-2.9%		N/A-31.2%£88.83M£12.54M12.1012
APH
Alliance Pharma
N/AGBX 64.70
flat		N/AN/A£350.32M£183.50MN/A91,000
AGY
Allergy Therapeutics
N/AGBX 5.10
-2.9%		N/A-35.6%£322.96M£57.29MN/A612
BXP
Beximco Pharmaceuticals
N/AGBX 54
-1.8%		N/A+7.2%£240.90M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat		N/AN/A£231.30M£89.11M45.89220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel